J&J nixes blood cancer deal with Argenx

Published: 7 June 2021

Johnson & Johnson has discontinued a collaboration and license agreement with Argenx for an anti-CD70 antibody against blood cancers.

Cusatuzumab is an investigational therapeutic antibody that targets CD-70, and J&J and Argenx originally began a collaboration on the drug in 2018.  

In a press release, the company state that “The decision is based upon Janssen's review of all available cusatuzumab data and in consideration of the evolving standard of care for the treatment of acute myeloid leukemia (AML). Final results from Janssen's clinical studies of cusatuzumab will be presented in the future.”

Despite the development, Argenyx are pressing ahead with development, stating: “Interim data from the Phase 1b ELEVATE trial support continued development in acute myeloid leukemia (AML) and argenx plans to evaluate options to enable a path forward.”

The Phase 1b ELEVATE trial, which is evaluating usatuzumab in combination with venetoclax and azacitidine in AML, is currently ongoing.